PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING (PBPK) OF PITAVASTATIN AND ATORVASTATIN TO PREDICT DRUG-DRUG INTERACTIONS (DDIS).

被引：0
|
作者：
Duan, P. [1 ]
Zhao, P. [2 ]
Zhang, L. [2 ]
机构：
[1] US FDA, Silver Spring, MD USA
[2] US FDA, Off Clin Pharmacol, Off Translat Sci, CDER, Silver Spring, MD USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PT-17
引用
收藏
页码：S16 / S17
页数：2
相关论文
共 50 条
  • [31] When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populations
    Sychterz, Caroline
    Galetin, Aleksandra
    Taskar, Kunal S.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2021, 42 (04) : 160 - 177
  • [32] Prediction of Drug-Drug Interactions Between Opioids and Overdosed Benzodiazepines Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
    Ji, Beihong
    Liu, Shuhan
    Xue, Ying
    He, Xibing
    Viet Hoang Man
    Xie, Xiang-Qun
    Wang, Junmei
    DRUGS IN R&D, 2019, 19 (03) : 297 - 305
  • [33] ANTIBODY-DRUG CONJUGATES (ADCS) DRUG INTERACTIONS CAN BE PREDICTED USING A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING APPROACH
    Mukadam, Sophie
    Samineni, Divya
    Wong, Harvey
    Shen, Ben-Quan
    Lu, Dan
    Girish, Sandhya
    Hop, Cornelis
    Jin, Yan Jin
    Li, Chunze
    Chen, Yuan
    DRUG METABOLISM REVIEWS, 2015, 47 : 118 - 118
  • [34] Physiologically-Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug-Drug Interactions
    Sahasrabudhe, Siddhee A.
    Cheng, Shen
    Al-Kofahi, Mahmoud
    Jarnes, Jeanine R.
    Weinreb, Neal J.
    Kartha, Reena, V
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) : 1254 - 1263
  • [35] Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
    Ueno, Takashi
    Miyajima, Yukiko
    Landry, Ishani
    Lalovic, Bojan
    Schuck, Edgar
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (05): : 455 - 466
  • [36] Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling
    Costales, Chester
    Lin, Jian
    Kimoto, Emi
    Yamazaki, Shinji
    Gosset, James R.
    Rodrigues, A. David
    Lazzaro, Sarah
    West, Mark A.
    West, Michael
    Varma, Manthena V. S.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (09): : 1018 - 1031
  • [37] Applied physiologically-based pharmacokinetic modeling to assess uridine diphosphate-glucuronosyltransferase-mediated drug-drug interactions for Vericiguat
    Frechen, Sebastian
    Ince, Ibrahim
    Dallmann, Andre
    Gerisch, Michael
    Jungmann, Natalia A.
    Becker, Corina
    Lobmeyer, Maximilian
    Trujillo, Maria E.
    Xu, Shiyao
    Burghaus, Rolf
    Meyer, Michaela
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (01): : 79 - 92
  • [38] Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach
    Hanley, Michael J.
    Yeo, Karen Rowland
    Tugnait, Meera
    Iwasaki, Shinji
    Narasimhan, Narayana
    Zhang, Pingkuan
    Venkatakrishnan, Karthik
    Gupta, Neeraj
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (04): : 624 - 637
  • [39] PREDICTION OF DRUG-DRUG INTERACTIONS (DDI) WITH A MODERATE CYP3A INDUCER: DEVELOPMENT AND VALIDATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL OF RIFABUTIN
    Sorour, M.
    Mundra, V.
    Zhang, H.
    Sahasranaman, S.
    Ou, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S75 - S75
  • [40] Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib: Understanding Complex Drug-Drug Interactions
    Chen, Yuan
    Ma, Fang
    Jones, Nicholas S.
    Yoshida, Kenta
    Chiang, Po-Chang
    Durk, Matthew R.
    Wright, Matthew R.
    Jin, Jin Yan
    Chinn, Leslie W.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (06): : 332 - 341
12345